Beta

Lixte biotechnology holdings, inc.LIXT.US Overview

US StockHealthcare
(No presentation for LIXT)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

LIXT AI Insights

LIXT Overall Performance

LIXT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LIXT Recent Performance

-5.26%

Lixte biotechnology holdings, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

LIXT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check LIXT's Trend

LIXT Key Information

LIXT Valuation Metrics

LIXT Profile

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Price of LIXT

LIXT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LIXT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
20.35
PB Ratio
5.79
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
20.35
PB Ratio
5.79
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is LIXT's latest earnings report released?

    The most recent financial report for Lixte biotechnology holdings, inc. (LIXT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LIXT's short-term business performance and financial health. For the latest updates on LIXT's earnings releases, visit this page regularly.

  • How much debt does LIXT have?

    As of the end of the reporting period, Lixte biotechnology holdings, inc. (LIXT) had total debt of 1.03M, with a debt ratio of 0.08. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LIXT have?

    At the end of the period, Lixte biotechnology holdings, inc. (LIXT) held Total Cash and Cash Equivalents of 5.11M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LIXT's EPS continuing to grow?

    According to the past four quarterly reports, Lixte biotechnology holdings, inc. (LIXT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LIXT?

    Lixte biotechnology holdings, inc. (LIXT)'s Free Cash Flow (FCF) for the period is -1.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 81.72% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.